Changchun High-Tech advances pipeline with two clinical trial approvals

Changchun High & New Technology Industry Group (SZSE:000661) has announced significant progress in its pharmaceutical pipeline, with its subsidiary, Jinsai Pharmaceutical, receiving approval from the National Medical Products Administration for clinical trials of two key products. The first approval concerns GenSci134 injection, a Class 1 biological product independently developed by Jinsai. This injection is intended for treating Adult Growth Hormone Deficiency (AGHD). AGHD, often resulting from various developmental and genetic factors, necessitates long-term or even lifelong replacement therapy, addressing a currently unmet clinical need.